159 related articles for article (PubMed ID: 8422085)
1. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.
Schneider LS; Olin JT; Pawluczyk S
Am J Psychiatry; 1993 Feb; 150(2):321-3. PubMed ID: 8422085
[TBL] [Abstract][Full Text] [Related]
2. L-deprenyl and physostigmine for the treatment of Alzheimer's disease.
Marin DB; Bierer LM; Lawlor BA; Ryan TM; Jacobson R; Schmeidler J; Mohs RC; Davis KL
Psychiatry Res; 1995 Oct; 58(3):181-9. PubMed ID: 8570774
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
[TBL] [Abstract][Full Text] [Related]
4. A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl.
Sunderland T; Molchan S; Lawlor B; Martinez R; Mellow A; Martinson H; Putnam K; Lalonde F
Int Psychogeriatr; 1992; 4 Suppl 2():291-309. PubMed ID: 1288668
[TBL] [Abstract][Full Text] [Related]
5. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
Filip V; Kolibás E
J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
[TBL] [Abstract][Full Text] [Related]
6. L-deprenyl in Alzheimer's disease: cognitive and behavioral effects.
Freedman M; Rewilak D; Xerri T; Cohen S; Gordon AS; Shandling M; Logan AG
Neurology; 1998 Mar; 50(3):660-8. PubMed ID: 9521253
[TBL] [Abstract][Full Text] [Related]
7. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
Jenike MA; Albert MS; Heller H; Gunther J; Goff D
J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
[TBL] [Abstract][Full Text] [Related]
8. An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. The Tacrine 970-6 Study Group.
Foster NL; Petersen RC; Gracon SI; Lewis K
Dementia; 1996; 7(5):260-6. PubMed ID: 8872417
[TBL] [Abstract][Full Text] [Related]
9. L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition.
Tariot PN; Cohen RM; Sunderland T; Newhouse PA; Yount D; Mellow AM; Weingartner H; Mueller EA; Murphy DL
Arch Gen Psychiatry; 1987 May; 44(5):427-33. PubMed ID: 3107514
[TBL] [Abstract][Full Text] [Related]
10. Tranylcypromine compared with L-deprenyl in Alzheimer's disease.
Tariot PN; Sunderland T; Cohen RM; Newhouse PA; Mueller EA; Murphy DL
J Clin Psychopharmacol; 1988 Feb; 8(1):23-7. PubMed ID: 3127432
[TBL] [Abstract][Full Text] [Related]
11. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.
Thal LJ; Schwartz G; Sano M; Weiner M; Knopman D; Harrell L; Bodenheimer S; Rossor M; Philpot M; Schor J; Goldberg A
Neurology; 1996 Dec; 47(6):1389-95. PubMed ID: 8960716
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Antuono PG
Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
[TBL] [Abstract][Full Text] [Related]
13. New drug interventions in Alzheimer's disease.
Stern GM
Curr Opin Neurol Neurosurg; 1992 Feb; 5(1):100-3. PubMed ID: 1623227
[No Abstract] [Full Text] [Related]
14. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
Chatellier G; Lacomblez L
BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
[TBL] [Abstract][Full Text] [Related]
15. The use of selegiline in Alzheimer's patients with behavior problems.
Goad DL; Davis CM; Liem P; Fuselier CC; McCormack JR; Olsen KM
J Clin Psychiatry; 1991 Aug; 52(8):342-5. PubMed ID: 1907964
[TBL] [Abstract][Full Text] [Related]
16. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study.
Gauthier S; Bouchard R; Lamontagne A; Bailey P; Bergman H; Ratner J; Tesfaye Y; Saint-Martin M; Bacher Y; Carrier L
N Engl J Med; 1990 May; 322(18):1272-6. PubMed ID: 2183056
[TBL] [Abstract][Full Text] [Related]
17. Potential role for estrogen replacement in the treatment of Alzheimer's dementia.
Schneider LS; Farlow MR; Pogoda JM
Am J Med; 1997 Sep; 103(3A):46S-50S. PubMed ID: 9344406
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of low-dose L-deprenyl in Alzheimer's disease.
Schneider LS; Pollock VE; Zemansky MF; Gleason RP; Palmer R; Sloane RB
J Geriatr Psychiatry Neurol; 1991; 4(3):143-8. PubMed ID: 1953966
[TBL] [Abstract][Full Text] [Related]
19. Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease.
Schneider LS; Farlow M
Ann N Y Acad Sci; 1997 Sep; 826():317-22. PubMed ID: 9329702
[TBL] [Abstract][Full Text] [Related]
20. Selegiline in the treatment of behavioural disturbance in Alzheimer's disease.
Lawlor BA; Aisen PS; Green C; Fine E; Schmeïdler J
Int J Geriatr Psychiatry; 1997 Mar; 12(3):319-22. PubMed ID: 9152715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
